Holding(s) in Company

RNS Number : 8465S

Allergy Therapeutics PLC

29 September 2014

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ

1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ⁱⁱ

Allergy Therapeutics PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the
notification obligation: ⁱⁱⁱ

Abbott Laboratories, an Illinois corporation (for further see, section 9)

4. Full name of shareholder(s)
(if different from 3.):^iv

CFR International SPA and Yissum Holding Limited (for further, see section 9)

5. Date of the transaction and date on
which the threshold is crossed or
reached: ^v

26 September 2014

6. Date on which issuer notified:

29 September 2014

7. Threshold(s) that is/are crossed or
reached: ^{vi, vii}

Over 48%

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Ordinary shares GBP 0.01

GB00B02LCQ05

Below 3%

N/A

198,710,723

N/A

48.5%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

198,710,723

48.5%

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: ^xxi

Through a series of controlled undertakings, Abbott Laboratories has an indirect holding of 99.9% of the shares in CFR Pharmaceuticals, SA.

CFR Pharmaceuticals SA's wholly owned subsidiary, CFR International SPA, holds 14.98% of the voting rights in Allergy Therapeutics plc directly and 33.53% of the voting rights in Allergy Therapeutics plc indirectly. CFR International SPA also has a 100% interest in Yissum Holding Limited, which directly holds 33.53% of shares in Allergy Therapeutics plc.

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease
to hold:

12. Date on which proxy holder will cease to hold
voting rights:

13. Additional information:

14. Contact name:

Laura Bentham

Baker & McKenzie LLP

15. Contact telephone number:

+44(0)207 919 1000